Daiwa: Downgrade China National Pharmaceutical Group (01099.HK) target price to HK$22.5, rating remains "Neutral"

According to the Zhitong Finance APP, Daiwa Securities issued a research report stating that the profit forecast for China National Pharmaceutical Group Corporation (01099.HK) for the years 2025 to 2030 has been revised down by 1% to 6%. The reason for this is due to a downward adjustment in sales forecasts for the medical equipment and pharmaceutical distribution department. The target price has been lowered from HK$23 to HK$22.5, with a rating of "buy".